CDH1 and hepatocellular carcinoma: As shown in Fig. 2 (A–C), based on 13 studies [22], [30], [34], [35], [38], [41], [42], [44], [49]–[53], we investigated whether and how E-cadherin expression impacted overall survival of patients with HCC by phasing three periods, one-year, three-year and five-year, respectively.